

REFERENCES

- Abdullah, L. N. and Chow, E. K.-H. (2013) ‘Mechanisms of chemoresistance in cancer stem cells’, *Clinical and Translational Medicine*, 2(1), p. 3. doi: 10.1186/2001-1326-2-3.
- Administration, U. S. F. and D. (2017) ‘Press Announcements - FDA approves new treatment for certain advanced or metastatic breast cancers’, *FDA News Release*. Available at: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm578071.htm>.
- Anders, C. K., Carey, L. a, Frazier, D. P. and Kendig, R. D. (2010) ‘NIH Public Access’, *Clinical Breast Cancer*, 9(5), pp. 423–440. doi: 10.3816/CBC.2009.s.008.Biology.
- Assefnia, S., Dakshanamurthy, S., Guidry Auvil, J. M., Hampel, C., Anastasiadis, P. Z., Kallakury, B., Uren, A., Foley, D. W., Brown, M. L., Shapiro, L., Brenner, M., Haigh, D. and Byers, S. W. (2014) ‘Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.’, *Oncotarget*, 5(6), pp. 1458–1474. doi: 10.18632/oncotarget.1538.
- Balko, J. M., Schwarz, L. J., Luo, N., Estrada, M. V., Giltane, J. M., Dávila-González, D., Wang, K., Sánchez, V., Dean, P. T., Combs, S. E., Hicks, D., Pinto, J. A., Landis, M. D., Doimi, F. D., Yelensky, R., Miller, V. A., Stephens, P. J., Rimm, D. L., Gómez, H., Chang, J. C., Sanders, M. E., Cook, R. S. and Arteaga, C. L. (2016) ‘Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence’, *Science Translational Medicine*, 8(334), p. 334ra53-334ra53. doi: 10.1126/scitranslmed.aad3001.
- Barbano, R., Pasculli, B., Rendina, M., Fontana, A., Fusilli, C., Copetti, M., Castellana, S., Valori, V. M., Morritti, M., Graziano, P., Luigi, C., Coco, M., Picardo, F., Mazza, T., Evron, E., Murgio, R., Maiello, E., Esteller, M., Fazio, V. M. and Parrella, P. (2017) ‘Stepwise analysis of MIR9 loci identifies MIR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients’, *Scientific Reports*, 7(February), pp. 1–12. doi: 10.1038/srep45283.
- Bertoli, G., Cava, C. and Castiglioni, I. (2015) ‘Micromas: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer’, *Theranostics*, 5(10), pp. 1122–1143. doi: 10.7150/thno.11543.
- Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. and Gianni, L. (2016) ‘Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease’, *Nature Reviews Clinical Oncology*. Nature

- Publishing Group, 13(11), pp. 674–690. doi: 10.1038/nrclinonc.2016.66.
- Boyer, M. J. and Cheng, T. (2008) ‘The CDK inhibitors: Potential targets for therapeutic stem cell manipulations?’, *Gene Therapy*, pp. 117–125. doi: 10.1038/sj.gt.3303064.
- Brenton, J. D., Carey, L. A., Ahmed, A. and Caldas, C. (2005) ‘Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?’, *Journal of Clinical Oncology*, pp. 7350–7360. doi: 10.1200/JCO.2005.03.3845.
- Bryja, V., Červenka, I. and Čajánek, L. (2017) ‘The connections of Wnt pathway components with cell cycle and centrosome: side effects or a hidden logic?’, *Critical Reviews in Biochemistry and Molecular Biology*, pp. 614–637. doi: 10.1080/10409238.2017.1350135.
- Cerqueira, A., Santamaría, D., Martínez-Pastor, B., Cuadrado, M., Fernández-Capetillo, O. and Barbacid, M. (2009) ‘Overall Cdk activity modulates the DNA damage response in mammalian cells’, *Journal of Cell Biology*, 187(6), pp. 773–780. doi: 10.1083/jcb.200903033.
- Chang, C. H., Huang, T. F., Lin, K. T., Hsu, C. C., Chang, W. L., Wang, S. W., Ko, F. N., Peng, H. C. and Chung, C. H. (2015a) ‘4-acetylanthroquinol B suppresses tumor growth and metastasis of hepatoma cells via blockade of translation-dependent signaling pathway and VEGF production’, *Journal of Agricultural and Food Chemistry*, 63(1), pp. 208–215. doi: 10.1021/jf504434v.
- Chang, C. H., Huang, T. F., Lin, K. T., Hsu, C. C., Chang, W. L., Wang, S. W., Ko, F. N., Peng, H. C. and Chung, C. H. (2015b) ‘4-acetylanthroquinol B suppresses tumor growth and metastasis of hepatoma cells via blockade of translation-dependent signaling pathway and VEGF production’, *Journal of Agricultural and Food Chemistry*, 63(1), pp. 208–215. doi: 10.1021/jf504434v.
- Chang, T. C., Yeh, C. T., Adebayo, B. O., Lin, Y. C., Deng, L., Rao, Y. K., Huang, C. C., Lee, W. H., Wu, A. T. H., Hsiao, M., Wu, C. H., Wang, L. S. and Tzeng, Y. M. (2015a) ‘4-Acetylanthroquinol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype’, *Toxicology and Applied Pharmacology*, 288(2), pp. 258–268. doi: 10.1016/j.taap.2015.07.025.
- Chang, T. C., Yeh, C. T., Adebayo, B. O., Lin, Y. C., Deng, L., Rao, Y. K., Huang, C. C., Lee, W. H., Wu, A. T. H., Hsiao, M., Wu, C. H., Wang, L. S. and Tzeng, Y. M. (2015b) ‘4-Acetylanthroquinol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype’, *Toxicology and Applied Pharmacology*. Elsevier Inc., 288(2), pp. 258–268. doi: 10.1016/j.taap.2015.07.025.
- Chen, X., Low, K. H., Alexander, A., Jiang, Y., Karakas, C., Hess, K. R., Carey, J. P. W., Bui, T. N., Vijayaraghavan, S., Evans, K. W., Yi, M., Ellis, D. C.,

- Cheung, K. L., Ellis, I. O., Fu, S., Meric-Bernstam, F., Hunt, K. K. and Keyomarsi, K. (2018) 'Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition', *Clinical Cancer Research*, 24(24), pp. 6594–6610. doi: 10.1158/1078-0432.CCR-18-1446.
- Cheung, D. G., Buzzetti, M., Croce, C. M. and Leva, G. di (2018) 'Abstract 1850: CDK inhibitor PHA-848125 preferentially inhibits proliferation of triple negative breast cancer and synergizes with cisplatin', *Cancer Research*, 78(13 Supplement), pp. 1850–1850. doi: 10.1158/1538-7445.am2018-1850.
- Chou, C. H., Shrestha, S., Yang, C. D., Chang, N. W., Lin, Y. L., Liao, K. W., Huang, W. C., Sun, T. H., Tu, S. J., Lee, W. H., Chiew, M. Y., Tai, C. S., Wei, T. Y., Tsai, T. R., Huang, H. T., Wang, C. Y., Wu, H. Y., Ho, S. Y., Chen, P. R., Chuang, C. H., Hsieh, P. J., Wu, Y. S., Chen, W. L., Li, M. J., Wu, Y. C., Huang, X. Y., Ng, F. L., Buddhakosai, W., Huang, P. C., Lan, K. C., Huang, C. Y., Weng, S. L., Cheng, Y. N., Liang, C., Hsu, W. L. and Huang, H. Da (2018) 'MiRTarBase update 2018: A resource for experimentally validated microRNA-target interactions', *Nucleic Acids Research*. Oxford University Press, 46(D1), pp. D296–D302. doi: 10.1093/nar/gkx1067.
- Chu, K., Cheng, C.-J., Ye, X., Lee, Y.-C., Zurita, A. J., Chen, D.-T., Yu-Lee, L.-Y., Zhang, S., Yeh, E. T., Hu, M. C.-T., Logothetis, C. J. and Lin, S.-H. (2008) 'Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone', *Molecular Cancer Research*, 6(8), pp. 1259–1267. doi: 10.1158/1541-7786.MCR-08-0077.
- Costa, R. L. B. and Gradishar, W. J. (2017) 'Triple-Negative Breast Cancer: Current Practice and Future Directions', *Journal of Oncology Practice*, 13(5), pp. 301–303. doi: 10.1200/JOP.2017.023333.
- Devine, D. J., Rostas, J. W., Metge, B. J., Das, S., Mulekar, M. S., Tucker, J. A., Grizzle, W. E., Buchsbaum, D. J., Shevde, L. A. and Samant, R. S. (2014) 'Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF- β /SMAD signaling.', *Oncogene*, 33(20), pp. 2620–8. doi: 10.1038/onc.2013.215.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D. and Bray, F. (2015) 'Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012', *International Journal of Cancer*, 136(5), pp. E359–E386. doi: 10.1002/ijc.29210.
- Filho, R. A. E.-A., Nicolas, A., Castro, T. L. P., Deplanche, M., Azevedo, V. A. C., Goossens, P. L., Taieb, F., Lina, G., Loir, Y. L. and Berkova, N. (2017) 'Corrigendum: Heterogeneous family of cyclomodulins: Smart weapons that allow bacteria to hijack the eukaryotic cell cycle and promote infections [Front. Cell. Infect. Microbiol., 7, (2017) (208)] doi:

- 10.3389/fcimb.2017.00208', *Frontiers in Cellular and Infection Microbiology*, 7(AUG). doi: 10.3389/fcimb.2017.00364.
- Fkih M'hamed, I., Privat, M., Ponelle, F., Penault-Llorca, F., Kenani, A. and Bignon, Y. J. (2015) 'Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers', *Cellular Oncology*, 38(6), pp. 433–442. doi: 10.1007/s13402-015-0239-3.
- Foster, I. (2008) 'Cancer: A cell cycle defect', *Radiography*, pp. 144–149. doi: 10.1016/j.radi.2006.12.001.
- Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., James, J. J., Maysuria, M., Mitton, J. D., Oliveri, P., Osborn, J. L., Peng, T., Ratcliffe, A. L., Webster, P. J., Davidson, E. H. and Hood, L. (2008) 'Direct multiplexed measurement of gene expression with color-coded probe pairs', *Nature Biotechnology*, 26(3), pp. 317–325. doi: 10.1038/nbt1385.
- Goel, S., DeCristo, M. J., McAllister, S. S. and Zhao, J. J. (2018) 'CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest', *Trends in Cell Biology*. Elsevier Ltd, pp. 911–925. doi: 10.1016/j.tcb.2018.07.002.
- Hakami, F., Darda, L., Stafford, P., Woll, P., Lambert, D. W. and Hunter, K. D. (2014) 'The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC)', *British Journal of Cancer*. Nature Publishing Group, 111(4), pp. 807–816. doi: 10.1038/bjc.2014.372.
- Hanahan, D. and Weinberg, R. A. (2011) 'Hallmarks of cancer: the next generation.', *Cell*, 144(5), pp. 646–74. doi: 10.1016/j.cell.2011.02.013.
- Iii, J. W. R., Pruitt, H. C., Metge, B. J., Mitra, A., Bailey, S. K., Bae, S., Singh, K. P., Devine, D. J., Dyess, D. L., Richards, W. O., Tucker, J. A., Shevde, L. A. and Samant, R. S. (2014) 'microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer', pp. 1–11.
- Jang, M. H., Kim, H. J., Gwak, J. M., Chung, Y. R. and Park, S. Y. (2017) 'Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer', *Human Pathology*, 68, pp. 69–78. doi: 10.1016/j.humpath.2017.08.026.
- Johansson, J., Berg, T., Kurzejamska, E., Pang, M., Tabor, V., Jansson, M., Roswall, P., Pietras, K., Sund, M., Religa, P. and Fuxe, J. (2013) 'MiR-155-mediated loss of C / EBP b shifts the TGF- b response from growth inhibition to epithelial-mesenchymal transition , invasion and metastasis in breast cancer'. Nature Publishing Group, 32(50), pp. 5614–5624. doi: 10.1038/onc.2013.322.
- Johnson, N. and Shapiro, G. I. (2010) 'Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors', *Expert Opinion on Therapeutic Targets*, 14(11), pp. 1199–1212. doi: 10.1517/14728222.2010.525221.
- Kastan, M. B. and Bartek, J. (2004) 'Cell-cycle checkpoints and cancer', *Nature*, pp.

- 316–323. doi: 10.1038/nature03097.
- Kim, S. J., Nakayama, S., Miyoshi, Y., Taguchi, T., Tamaki, Y., Matsushima, T., Torikoshi, Y., Tanaka, S., Yoshida, T., Ishihara, H. and Noguchi, S. (2008) ‘Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer.’, *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*, 19(1), pp. 68–72. doi: 10.1093/annonc/mdm358.
- Knudsen, E. S. and Witkiewicz, A. K. (2017) ‘The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies’, *Trends in Cancer*. Elsevier Inc., pp. 39–55. doi: 10.1016/j.trecan.2016.11.006.
- Kong, W., He, L., Richards, E. J., Challa, S., Xu, C. X., Permeth-Wey, J., Lancaster, J. M., Coppola, D., Sellers, T. A., Djeu, J. Y. and Cheng, J. Q. (2014) ‘Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer’, *Oncogene*, 33(6), pp. 679–689. doi: 10.1038/onc.2012.636.
- Kwon, J., Eom, K., Koo, T. R., Kim, B. H., Kang, E., Kim, S., Kim, Y. J., Park, S. Y. and Kim, I. A. (2017) ‘Breast Cancer A Prognostic Model for Patients with Triple-Negative Breast Cancer : Importance of the Modified Nottingham Prognostic Index and Age Patient identification’, *J Breast Cancer*, 20(1), pp. 65–73.
- Largillier, R., Ferrero, J.-M., Doyen, J., Barriere, J., Namer, M., Mari, V., Courdi, A., Hannoun-Levi, J. M., Ettore, F., Birtwisle-Peyrottes, I., Balu-Maestro, C., Marcy, P. Y., Raoust, I., Lallement, M. and Chamorey, E. (2008) ‘Prognostic factors in 1038 women with metastatic breast cancer’, *Annals of Oncology*, 19(12), pp. 2012–2019. doi: 10.1093/annonc/mdn424.
- Lebert, J. M., Lester, R., Powell, E., Seal, M. and McCarthy, J. (2018) ‘Advances in the systemic treatment of triple-negative breast cancer’, *Current Oncology*, pp. S142–S150. doi: 10.3747/co.25.3954.
- Lin, Y. W. and Chiang, B. H. (2011) ‘4-acetylanthroquinol B isolated from *antrodia cinnamomea* arrests proliferation of human hepatocellular carcinoma HepG2 cell by affecting p53, p21 and p27 levels’, *Journal of Agricultural and Food Chemistry*, 59(16), pp. 8625–8631. doi: 10.1021/jf2011326.
- Liu, M., Bamodu, O. A., Huang, W. C., Zucha, M. A., Lin, Y. K., Wu, A. T. H., Huang, C. C., Lee, W. H., Yuan, C. C., Hsiao, M., Deng, L., Tzeng, Y. M. and Yeh, C. T. (2017a) ‘4-Acetylanthroquinol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway’, *Toxicology and Applied Pharmacology*, 325, pp. 48–60. doi: 10.1016/j.taap.2017.04.003.
- Liu, M., Bamodu, O. A., Huang, W. C., Zucha, M. A., Lin, Y. K., Wu, A. T. H., Huang, C. C., Lee, W. H., Yuan, C. C., Hsiao, M., Deng, L., Tzeng, Y. M. and Yeh, C. T. (2017b) ‘4-Acetylanthroquinol B suppresses autophagic

- flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway', *Toxicology and Applied Pharmacology*. Elsevier Inc, 325, pp. 48–60. doi: 10.1016/j.taap.2017.04.003.
- Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., Han, Y., Yin, P., Kim, J. J., Lee, S. B., Lin, J., Zhang, L., Zhang, J., Nowsheen, S., Wang, L., Boughey, J., Goetz, M. P., Yuan, J. and Lou, Z. (2017) 'CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1', *Nature Communications*, 8. doi: 10.1038/ncomms13923.
- Liu, Y., Zhao, J., Zhang, P.-Y., Zhang, Y., Sun, S.-Y., Yu, S.-Y. and Xi, Q.-S. (2012) 'MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis.', *Medical science monitor: international medical journal of experimental and clinical research*, 18(8), p. BR299-308. doi: 883262 [pii].
- Ma, L., Teruya-Feldstein, J. and Weinberg, R. a (2007) 'Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.', *Nature*, 449(7163), pp. 682–8. doi: 10.1038/nature06174.
- Mohammadi, A., Mansoori, B. and Baradaran, B. (2017) 'Regulation of miRNAs by herbal medicine: An emerging field in cancer therapies', *Biomedicine and Pharmacotherapy*. Elsevier Masson SAS, 86, pp. 262–270. doi: 10.1016/j.biopha.2016.12.023.
- Nakayama, K. I. and Nakayama, K. (2006) 'Ubiquitin ligases: Cell-cycle control and cancer', *Nature Reviews Cancer*, pp. 369–381. doi: 10.1038/nrc1881.
- Niehrs, C. and Acebron, S. P. (2012) 'Mitotic and mitogenic Wnt signalling', *EMBO Journal*, pp. 2705–2713. doi: 10.1038/emboj.2012.124.
- Owens, T. W. and Naylor, M. J. (2013) 'Breast cancer stem cells', *Frontiers in Physiology*. doi: 10.3389/fphys.2013.00225.
- Pei, Y. fei, Lei, Y. and Liu, X. qiang (2016) 'MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1', *Biochimica et Biophysica Acta - Molecular Basis of Disease*. Elsevier B.V., 1862(11), pp. 2177–2185. doi: 10.1016/j.bbadis.2016.08.014.
- Peng, Y. and Croce, C. M. (2016) 'The role of MicroRNAs in human cancer', *Signal Transduction and Targeted Therapy*, 1(November 2015), p. 15004. doi: 10.1038/sigtrans.2015.4.
- Phuah, N. H. and Nagoor, N. H. (2014) 'Regulation of MicroRNAs by Natural Agents: New Strategies in Cancer Therapies', *BioMed Research International*, 2014, pp. 1–17. doi: 10.1155/2014/804510.
- Pohlodek, K., Tan, Y. Y., Singer, C. F. and Gschwantler-Kaulich, D. (2016) 'Cadherin-11 expression is upregulated in invasive human breast cancer', *Oncology Letters*, 12(6), pp. 4393–4398. doi: 10.3892/ol.2016.5236.
- Rakha, E. A. and Chan, S. (2011) 'Metastatic Triple-negative Breast Cancer',

- Clinical Oncology*, 23(9), pp. 587–600. doi: 10.1016/j.clon.2011.03.013.
- Satcher, R. L., Pan, T., Cheng, C. J., Lee, Y. C., Lin, S. C., Yu, G., Li, X., Hoang, A. G., Tamboli, P., Jonasch, E., Gallick, G. E. and Lin, S. H. (2014) ‘Cadherin-11 in renal cell carcinoma bone metastasis’, *PLoS ONE*, 9(2), p. e89880. doi: 10.1371/journal.pone.0089880.
- Schie, I. W. and Huser, T. (2013) ‘Methods and applications of Raman microspectroscopy to single-cell analysis’, in *Applied Spectroscopy*, pp. 813–828. doi: 10.1366/12-06971.
- Shah, A., Bloomquist, E., Tang, S., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., Chang, C. J. G., Patel, P., Alebachew, E., Tilley, A., Pierce, W. F., Ibrahim, A., Blumenthal, G. M., Sridhara, R., Beaver, J. A. and Pazdur, R. (2018) ‘FDA approval: Ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer’, *Clinical Cancer Research*, pp. 2999–3004. doi: 10.1158/1078-0432.CCR-17-2369.
- Singh, A. and Settleman, J. (2010) ‘EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.’, *Oncogene*, 29(34), pp. 4741–51. doi: 10.1038/onc.2010.215.
- Singh, U., Chashoo, G., Khan, S. U., Mahajan, P., Nargotra, A., Mahajan, G., Singh, A., Sharma, A., Minto, M. J., Guru, S. K., Aruri, H., Thatikonda, T., Sahu, P., Chibber, P., Kumar, V., Mir, S. A., Bharate, S. S., Madishetti, S., Nandi, U., Singh, G., Mondhe, D. M., Bhushan, S., Malik, F., Mignani, S., Vishwakarma, R. A. and Singh, P. P. (2017) ‘Design of Novel 3-Pyrimidinylzaindole CDK2/9 Inhibitors with Potent in Vitro and in Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model’, *Journal of Medicinal Chemistry*, 60(23), pp. 9470–9489. doi: 10.1021/acs.jmedchem.7b00663.
- Su, Y., Wu, H., Pavlosky, A., Zou, L. L., Deng, X., Zhang, Z. X. and Jevnikar, A. M. (2016) ‘Regulatory non-coding RNA: new instruments in the orchestration of cell death’, *Cell death & disease*, 7(8), p. e2333. doi: 10.1038/cddis.2016.210.
- Talhouk, A., Kommoss, S., Mackenzie, R., Cheung, M., Leung, S., Chiu, D. S., Kalloger, S. E., Huntsman, D. G., Chen, S., Intermaggio, M., Gronwald, J., Chan, F. C., Ramus, S. J., Steidl, C., Scott, D. W. and Anglesio, M. S. (2016) ‘Single-patient molecular testing with nanostring ncounter data using a reference-based strategy for batch effect correction’, *PLoS ONE*, 11(4), pp. 1–18. doi: 10.1371/journal.pone.0153844.
- Tarasewicz, E., Rivas, L., Hamdan, R., Dokic, D., Parimi, V., Bernabe, B. P., Thomas, A., Shea, L. D. and Jeruss, J. S. (2014) ‘Inhibition of CDK-Mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells’, *Cell Cycle*, 13(20), pp. 3191–3201. doi: 10.4161/15384101.2014.950126.

- Uhlen, M., Fagerberg, L., Hallstrom, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., Olsson, I., Edlund, K., Lundberg, E., Navani, S., Szigartyo, C. A.-K., Odeberg, J., Djureinovic, D., Takanen, J. O., Hober, S., Alm, T., Edqvist, P.-H., Berling, H., Tegel, H., Mulder, J., Rockberg, J., Nilsson, P., Schwenk, J. M., Hamsten, M., von Feilitzen, K., Forsberg, M., Persson, L., Johansson, F., Zwahlen, M., von Heijne, G., Nielsen, J. and Ponten, F. (2015) 'Tissue-based map of the human proteome', *Science*, 347(6220), pp. 1260419–1260419. doi: 10.1126/science.1260419.
- Walker, A. J., Wedam, S., Amiri-Kordestani, L., Bloomquist, E., Tang, S., Sridhara, R., Chen, W., Palmby, T. R., Zirkelbach, J. F., Fu, W., Liu, Q., Tilley, A., Kim, G., Kluetz, P. G., McKee, A. E. and Pazdur, R. (2016) 'FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer', *Clinical Cancer Research*, 22(20), pp. 4968–4972. doi: 10.1158/1078-0432.CCR-16-0493.
- Wang, H., Horbinski, C., Wu, H., Liu, Y., Sheng, S., Liu, J., Weiss, H., Stromberg, A. J. and Wang, C. (2016) 'NanoStringDiff: A novel statistical method for differential expression analysis based on NanoString nCounter data', *Nucleic Acids Research*, 44(20), p. e151. doi: 10.1093/nar/gkw677.
- Widodo, I., Dwianingsih, E. K., Triningsih, E., Utoro, T. and Soeripto (2014) 'Clinicopathological features of Indonesian breast cancers with different molecular subtypes', *Asian Pacific Journal of Cancer Prevention*, 15(15), pp. 6109–6113. doi: 10.7314/APJCP.2014.15.15.6109.
- Wu, J., Kaklamani, V. G., Jeruss, J. S., Konopka, K., Thomas, A. L., Decker, J. T., Shea, L. D., Dokic, D., Rao, S. S., Stoehr, J. and Wan, L. (2017) 'Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer', *Oncotarget*, 8(48). doi: 10.18632/oncotarget.20202.
- Yu, X., Zheng, H., Chan, M. T. V. and Wu, W. K. K. (2017) 'BANCR: A cancer-related long non-coding RNA', *American Journal of Cancer Research*, pp. 1779–1787. doi: 10.4149/neo.